Pancreatic cancer will be the second leading cause of
cancer-related mortality worldwide due to its high rate of
metastasis.
Cathepsins (CATs) are effectors of invasive growth in various
cancers. Currently, targeting CATs represents an attractive strategy for the treatment of highly metastatic
cancers with high CATs activity, such as
pancreatic cancer. To develop a stronger antimetastatic agent,
ASPER-29, a novel inhibitor of CATs designed by using the
asperphenamate derivative
BBP as a lead compound, was synthesized, and its therapeutic potential in
pancreatic cancer metastasis was investigated in this study. Molecular docking and
enzyme inhibition assays proved that
ASPER-29 can inhibit the activity of CAT-L and CAT-S by binding with these
enzymes in classical action modes. Furthermore,
ASPER-29 significantly inhibited the activity of CAT-L and CAT-S but had no effect on their expression in PANC-1 and BxPC-3 cells. The in vitro antimetastatic activities of
ASPER-29 were examined by wound healing and Transwell chamber assays. We found that
ASPER-29 inhibited the migration and invasion of PANC-1 and BxPC-3 cells in a concentration-dependent manner. Moreover, the in vivo antimetastatic effects of
ASPER-29 were confirmed in a mouse
xenotransplantation model. H&E staining and immunohistochemistry assays of Ki67 and CEACAM6 proved that
ASPER-29 treatment significantly blocked the
metastasis of
pancreatic cancer cells to lung and liver tissues. Additionally, the activity of both CAT-L and CAT-S was markedly inhibited in the lung and liver tissues of ASPER-29-administered mice compared with the mice in the model group, suggesting that the
metastasis-blocking effect of
ASPER-29 should be mediated via inhibition of the activity of CAT-L and CAT-S in
pancreatic cancer cells. Together, our results demonstrated that
ASPER-29, as a novel inhibitor of CAT-L and CAT-S, possessed the evident ability to block the
metastasis of
pancreatic cancer cells.